Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2022 06:30 ET | Source: Affimed N.V.

Affimed Reports 2021 Financial Results and Highlights Recent Operational Progress

Completed enrollment for AFM13-202 monotherapy study, REDIRECT, and on track to report topline data in the second half of 2022Presented interim data in December 2021 of the combination study of AFM13...
March 24, 2022 06:30 ET | Source: Affimed N.V.

Affimed to Report Full Year 2021 Financial Results & Corporate Update on March 31, 2022

HEIDELBERG, Germany, March 24, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
March 08, 2022 16:35 ET | Source: Affimed N.V.

Affimed Announces Clinical Updates at the Annual Meeting of the American Association for Cancer Research

In a Clinical Trials Plenary Session an update of the phase 1/2 study evaluating cord blood-derived NK cells that are pre-complexed with the innate cell engager AFM13 in patients with CD30-positive...
February 09, 2022 16:05 ET | Source: Affimed N.V.

Affimed Announces Publication of Preclinical Data Demonstrating Cytotoxic Potency and Efficacy of NK Cells Precomplexed with Innate Cell Engagers after Freezing & Thawing

Precomplexing NK cells with Innate Cell Engagers (ICE® molecules) results in a CAR-like NK cell product, whose magnitude and specificity of antibody-dependent cellular cytotoxicity (ADCC) remain...
February 08, 2022 06:30 ET | Source: Affimed N.V.

Affimed to Present at Upcoming Investor Events

HEIDELBERG, Germany, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
January 06, 2022 06:30 ET | Source: Affimed N.V.

Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update

Enrollment of REDIRECT study (AFM13-202) is completed; topline clinical readout expected in 2H 2022FDA approves protocol amendment to allow for (i) enrollment of up to 40 patients at the highest dose...
January 05, 2022 06:30 ET | Source: Affimed N.V.

Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference

HEIDELBERG, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
December 13, 2021 09:05 ET | Source: Affimed N.V.

Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition

AFM28 effectively induces depletion of leukemic cells in patient bone marrow samples and demonstrates the anticipated good safety profile and pharmacologic activity in cynomolgus monkeysPre-complexing...
December 09, 2021 06:30 ET | Source: Affimed N.V.

Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13

For the 13 patients treated at the recommended phase 2 dose (RP2D) the response rate after one cycle of treatment remains at 100% with a 38.5% complete response (CR) rate; one additional patient...
December 08, 2021 06:30 ET | Source: Affimed N.V.

Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche’s Anti-PD-L1 Checkpoint Inhibitor Atezolizumab

HEIDELBERG, Germany, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...